Classification of cardio-oncology syndromes in assessing the interaction of cardiovascular diseases and cancer

Improvement in early diagnosis and treatment increased life expectancy in patients with malignant neoplasms (MN). There are about 17 million cancer survivors in the United States today. Over the next 10 years, a 31% increase in the number of survivors is predicted. More than 22 million people projected to survive by 2030. In the last decade, cardiologists and oncologists provided clinical and experimental evidence that cancers, as well as their treatment, have a negative impact on cardiovascular system. This creates clinical problems for the management of such patients. In parallel, there is a particular attention to the idea that cardiovascular disease (CVD) may represent a pro-oncogenic condition. Among cancer survivors, CVD is the leading cause of non-cancer mortality. Epidemiological evidence suggests higher risk of MN in patients with CVD. The purpose of this article is to summarize and analyze data on classification of cardio-oncology syndromes (COS) characterizing the relationship between CVD and cancers. Searching for literature data was performed in the PubMed, Clinical Trials, Google Scholar, eLibrary, CyberLeninka databases. A group of foreign authors proposed a classification based on 5 types of COS. We propose to add another type of COS to this classification (related to comorbidity affecting the outcome of anticancer therapy).